---
figid: PMC9264050__jtd-14-06-2089-f2
pmcid: PMC9264050
image_filename: jtd-14-06-2089-f2.jpg
figure_link: /pmc/articles/PMC9264050/figure/f2/
number: Figure 2
figure_title: ''
caption: 'Pirfenidone inhibits damage to RLE-6TN cells by inhibiting bleomycin through
  TNF-α. (A) MTT assays to assess cell viability in each group. (B) Protein expression
  levels of STAT3, pSTAT3, α-SMA, vimentin, and KL-6 in each group. (C-G) Grayscale
  image of α-SMA, vimentin, p-STAT3, STAT3, and KL-6 protein expression in each group.
  ***, P<0.01, **, P<0.05, and *, P<0.1; ##, P<0.05 compared with the PMC group; and
  #, P<0.1 compared with the PMC group. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
  bromide; NTC, nontreated group; MC, model group; PMC, pirfenidone treatment model
  group; IPMC, infliximab group; α-SMA, α-smooth muscle actin; STAT3, signal transducer
  and activator of transcription 3; p-STAT3, phosphorylated signal transducer and
  activator of transcription 3; MUC1, Mucin 1; KL-6, Krebs Von den Lungen-6; GAPDH,
  glyceraldehyde 3-phosphate dehydrogenase.'
article_title: Pirfenidone inhibits cell fibrosis in connective tissue disease-associated
  interstitial lung disease by targeting the TNF-α/STAT3/KL6 pathway.
citation: Yanhua Zuo, et al. J Thorac Dis. 2022 Jun;14(6):2089-2102.
year: '2022'

doi: 10.21037/jtd-22-41
journal_title: Journal of Thoracic Disease
journal_nlm_ta: J Thorac Dis
publisher_name: AME Publishing Company

keywords:
- Pirfenidone
- connective tissue disease-associated interstitial lung disease (CTD-ILD)
- tumor necrosis factor-α (TNF-α)
- signal transducer and activator of transcription 3 (STAT3)
- Krebs Von den Lungen-6 (KL-6)

---
